IN BRIEF (Page 17)

Eli Lilly beats Street view

Eli Lilly and Co posted better-than-expected quarterly profit yesterday as sales of its top-selling prescription drugs beat projections, and the drugmaker raised its full-year earnings forecast.

Net income was $941.8 million, or 86 cents per share, compared with a net loss of $465.6 million, or 43 cents per share, a year earlier, when Lilly took big charges related to a marketing probe of Zyprexa. Excluding those charges, Lilly posted earnings of $1.20 per share. On that basis, analysts' average forecast was $1.02, according to Thomson Reuters.